Amphastar (AMPH) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Amphastar Pharmaceuticals (AMPH) reported $186.52 million in revenue for the quarter ended December 2024, representing a year-over-year increase of 4.7%. EPS of $0.92 for the same period compares to $0.88 a year ago.The reported revenue represents a surprise of -1.08% over the Zacks Consensus Estimate of $188.55 million. With the consensus EPS estimate being $0.96, the EPS surprise was -4.17%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Amphastar performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Net revenues- Primatene MIST: $28.94 million versus the two-analyst average estimate of $29.02 million. Net revenues- Epinephrine: $18.70 million compared to the $18.93 million average estimate based on two analysts. Net revenues- Lidocaine: $14.40 million compared to the $14.92 million average estimate based on two analysts. Net revenues- Naloxone: $3.60 million versus $3.72 million estimated by two analysts on average. Net revenues- Glucagon: $25.62 million versus the two-analyst average estimate of $25.99 million. Net revenues- Enoxaparin: $3.73 million versus $6.07 million estimated by two analysts on average. Net revenues- Phytonadione: $11.17 million versus the two-analyst average estimate of $10.55 million. View all Key Company Metrics for Amphastar here>>>Shares of Amphastar have returned -14.3% over the past month versus the Zacks S&P 500 composite's -2.2% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.5 Stocks Set to DoubleEach was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.Today, See These 5 Potential Home Runs >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Amphastar Pharmaceuticals, Inc. (AMPH): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks